“[It’s] not just talking about psilocybin, but discussing the whole experience that surrounds the actual delivery from the molecule,” says Matt Emmer, vice president of health treatment follow at publicly traded Canadian company Subject Trip Health, which operates a psilocybin center in Amsterdam.In assistance of its initiatives to become the